Beaufort Securities reiterated GlaxoSmithKline PLC (LON:GSK) to Buy in a report released today.
- Updated: September 15, 2016
Beaufort Securities has reiterated GlaxoSmithKline PLC(LON:GSK) to Buy in a report released on 9/16/2016.
Previously on 9/15/2016, Liberum Capital reported about GlaxoSmithKline PLC(LON:GSK) raised the target price at 1,900.00GBX that suggested an upside of 0.18%.
Only yesterday GlaxoSmithKline PLC (LON:GSK) traded 0.06% higher at 1,625.25GBX. GlaxoSmithKline PLC’s 50-day moving average is 1,662.11GBX and its two hundred day moving average is 1,522.63GBX. With the last close up 6.03% from the two hundred day moving average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the same time period. Trade volume was was down over the average, with 2,100,729 shares of GSK changing hands under the typical 8,900,690 shares..
Recent Performance Graphic:
GlaxoSmithKline PLC has a PE of 2,691 with a one-year low of 1,227.50GBX and a 52 week high of 1,716.50GBX. GSK’s market capitalization is presently 0.0 GBX.
A total of 24 firms have reported on the company. Three firms rate the stock a strong buy, six firms rate the stock a buy, 17 firms rate the company a hold, two analysts rate the stock to underperform, and lastly 0 brokeragesrate the company as sell with a one year target of 1,577.33GBX
General Information About GlaxoSmithKline PLC (LON:GSK)
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, and respiratory and rare diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.